

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Contezolid Acefosamil
Therapeutic Area : Podiatry
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
MicuRx: Contezolid Phase III Trial Endorsed, Promising for Diabetic Foot Infection
Details : MRX-4 (contezolid acefosamil) is being evaluating in the late-stage clinical trials studies for the treatment of patients suffering from Diabetic Foot Infection.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
February 25, 2025
Lead Product(s) : Contezolid Acefosamil
Therapeutic Area : Podiatry
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Contezolid Acefosamil
Therapeutic Area : Podiatry
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Contezolid Acefosamil is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetic Foot.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
May 11, 2022
Lead Product(s) : Contezolid Acefosamil
Therapeutic Area : Podiatry
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Contezolid Acefosamil
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Contezolid Acefosamil is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Skin Diseases, Bacterial.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 20, 2018
Lead Product(s) : Contezolid Acefosamil
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Contezolid Acefosamil
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Worldwide Clinical Trials
Deal Size : Inapplicable
Deal Type : Inapplicable
Single Dose Escalation and Multiple Dose Escalation Trial of an Intravenous Formulation of MRX-4
Details : MRX-4 is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 26, 2017
Lead Product(s) : Contezolid Acefosamil
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Worldwide Clinical Trials
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Contezolid Acefosamil
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Worldwide Clinical Trials
Deal Size : Inapplicable
Deal Type : Inapplicable
Single Dose and Multiple Dose Escalation Trial of an Oral Formulation of MRX-4
Details : MRX-4 is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 26, 2017
Lead Product(s) : Contezolid Acefosamil
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Worldwide Clinical Trials
Deal Size : Inapplicable
Deal Type : Inapplicable
